Back to Newsroom

Novavax Initiates Phase 1/2 Trial of NanoFlu™ Vaccine in Older Adults

GAITHERSBURG, Md., Sept. 19, 2017 (GLOBE NEWSWIRE) — Novavax, Inc., (Nasdaq:NVAX) today announced the enrollment of the first participant in a Phase 1/2 clinical trial of its nanoparticle influenza vaccine candidate including its proprietary Matrix-M™ adjuvant (NanoFlu™) in older adults.
READ MORE…